Breaking the DNA damage response to improve cervical cancer treatment

Ferlay, 2010, Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008, Int J Cancer, 127, 2893, 10.1002/ijc.25516 Quinn, 2006, Carcinoma of the cervix uteri. FIGO 26th annual report on the results of treatment in gynecological cancer, Int J Gynaecol Obstet, 95, S43, 10.1016/S0020-7292(06)60030-1 Rose, 1999, Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer, N Engl J Med, 340, 1144, 10.1056/NEJM199904153401502 Jackson, 2009, The DNA-damage response in human biology and disease, Nature, 461, 1071, 10.1038/nature08467 Hegi, 2005, MGMT gene silencing and benefit from temozolomide in glioblastoma, N Engl J Med, 352, 997, 10.1056/NEJMoa043331 Bryant, 2005, Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase, Nature, 434, 913, 10.1038/nature03443 Farmer, 2005, Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy, Nature, 434, 917, 10.1038/nature03445 Fong, 2009, Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers, N Engl J Med, 361, 123, 10.1056/NEJMoa0900212 Kelland, 1988, Induction and rejoining of DNA double-strand breaks in human cervix carcinoma cell lines of differing radiosensitivity, Radiat Res, 116, 526, 10.2307/3577394 Wilson, 2000, Expression of Ku70 correlates with survival in carcinoma of the cervix, Br J Cancer, 83, 1702, 10.1054/bjoc.2000.1510 Doll, 2013, The significance of tumoral ERCC1 status in patients with locally advanced cervical cancer treated with chemoradiation therapy: a multicenter clinicopathologic analysis, Int J Radiat Oncol Biol Phys, 85, 721, 10.1016/j.ijrobp.2012.06.021 Walboomers, 1999, Human papillomavirus is a necessary cause of invasive cervical cancer worldwide, J Pathol, 189, 12, 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F von Knebel Doeberitz, 1992, Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV E6–E7 anti-sense RNA, Int J Cancer, 51, 831, 10.1002/ijc.2910510527 Dyson, 1989, The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product, Science, 243, 934, 10.1126/science.2537532 Werness, 1990, Association of human papillomavirus types 16 and 18 E6 proteins with p53, Science, 248, 76, 10.1126/science.2157286 Moody, 2010, Human papillomavirus oncoproteins: pathways to transformation, Nat Rev Cancer, 10, 550, 10.1038/nrc2886 Rieckmann, 2013, HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacity, Radiother Oncol, 107, 242, 10.1016/j.radonc.2013.03.013 Seiwert, 2015, Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas, Clin Cancer Res, 21, 632, 10.1158/1078-0432.CCR-13-3310 Hufbauer, 2015, Human papillomavirus mediated inhibition of DNA damage sensing and repair drives skin carcinogenesis, Mol Cancer, 14, 183, 10.1186/s12943-015-0453-7 Park, 2014, Human papillomavirus type 16 E7 oncoprotein causes a delay in repair of DNA damage, Radiother Oncol, 113, 337, 10.1016/j.radonc.2014.08.026 Wallace, 2015, β-HPV 5 and 8 E6 disrupt homology dependent double strand break repair by attenuating BRCA1 and BRCA2 expression and foci formation, PLoS Pathog, 11, e1004687, 10.1371/journal.ppat.1004687 Iftner, 2002, Interference of papillomavirus E6 protein with single-strand break repair by interaction with XRCC1, EMBO J, 21, 4741, 10.1093/emboj/cdf443 Shin, 2006, HPV-16 E6 oncoprotein impairs the fidelity of DNA end-joining via p53-dependent and -independent pathways, Int J Oncol, 28, 209 Ojesina, 2014, Landscape of genomic alterations in cervical carcinomas, Nature, 506, 371, 10.1038/nature12881 Tang, 2013, The landscape of viral expression and host gene fusion and adaptation in human cancer, Nat Commun, 4, 2513, 10.1038/ncomms3513 Schiffman, 2007, Human papillomavirus and cervical cancer, Lancet, 370, 890, 10.1016/S0140-6736(07)61416-0 Smith, 2007, Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update, Int J Cancer, 121, 621, 10.1002/ijc.22527 Thomas, 2008, Human papillomaviruses, cervical cancer and cell polarity, Oncogene, 27, 7018, 10.1038/onc.2008.351 Doorbar, 2012, The biology and life-cycle of human papillomaviruses, Vaccine, 30, F55, 10.1016/j.vaccine.2012.06.083 Fehrmann, 2003, Human papillomaviruses: targeting differentiating epithelial cells for malignant transformation, Oncogene, 22, 5201, 10.1038/sj.onc.1206554 Münger, 1989, Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product, EMBO J, 8, 4099, 10.1002/j.1460-2075.1989.tb08594.x Khleif, 1996, Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity, Proc Natl Acad Sci USA, 93, 4350, 10.1073/pnas.93.9.4350 Jones, 1997, Analysis of the p53-mediated G1 growth arrest pathway in cells expressing the human papillomavirus type 16 E7 oncoprotein, J Virol, 71, 2905, 10.1128/JVI.71.4.2905-2912.1997 Bartkova, 2005, DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis, Nature, 434, 864, 10.1038/nature03482 Gorgoulis, 2005, Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions, Nature, 434, 907, 10.1038/nature03485 Kastan, 2004, Cell-cycle checkpoints and cancer, Nature, 432, 316, 10.1038/nature03097 Vogelstein, 2000, Surfing the p53 network, Nature, 408, 307, 10.1038/35042675 Bester, 2011, Nucleotide deficiency promotes genomic instability in early stages of cancer development, Cell, 145, 435, 10.1016/j.cell.2011.03.044 Zur Hausen, 1999, Immortalization of human cells and their malignant conversion by high risk human papillomavirus genotypes, Semin Cancer Biol, 9, 405, 10.1006/scbi.1999.0144 Forbes, 2014, COSMIC: exploring the world’s knowledge of somatic mutations in human cancer, Nucleic Acids Res, 43, D805, 10.1093/nar/gku1075 Crook, 1992, Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus-negative tumours, Lancet, 339, 1070, 10.1016/0140-6736(92)90662-M McIntyre, 2013, PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy, Gynecol Oncol, 128, 409, 10.1016/j.ygyno.2012.12.019 Wingo, 2009, Somatic LKB1 mutations promote cervical cancer progression, PLoS ONE, 4, e5137, 10.1371/journal.pone.0005137 Wright, 2013, Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix, Cancer, 119, 3776, 10.1002/cncr.28288 Hermeking, 1997, 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression, Mol Cell, 1, 3, 10.1016/S1097-2765(00)80002-7 Khanna, 2001, DNA double-strand breaks: signaling, repair and the cancer connection, Nat Genet, 27, 247, 10.1038/85798 Uziel, 2003, Requirement of the MRN complex for ATM activation by DNA damage, EMBO J, 22, 5612, 10.1093/emboj/cdg541 Bakkenist, 2003, DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation, Nature, 421, 499, 10.1038/nature01368 Matsuoka, 2007, ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage, Science, 316, 1160, 10.1126/science.1140321 Ahn, 2000, Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation, Cancer Res, 60, 5934 Matsuoka, 1998, Linkage of ATM to cell cycle regulation by the Chk2 protein kinase, Science, 282, 1893, 10.1126/science.282.5395.1893 el-Deiry, 1993, WAF1, a potential mediator of p53 tumor suppression, Cell, 75, 817, 10.1016/0092-8674(93)90500-P Harper, 1993, The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases, Cell, 75, 805, 10.1016/0092-8674(93)90499-G Zeman, 2014, Causes and consequences of replication stress, Nat Cell Biol, 16, 2, 10.1038/ncb2897 Mailand, 2000, Rapid destruction of human Cdc25A in response to DNA damage, Science, 288, 1425, 10.1126/science.288.5470.1425 López-Contreras, 2010, The ATR barrier to replication-born DNA damage, DNA Repair (Amst), 9, 1249, 10.1016/j.dnarep.2010.09.012 Schoppy, 2012, Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR, J Clin Invest, 122, 241, 10.1172/JCI58928 López-Contreras, 2012, An extra allele of Chk1 limits oncogene-induced replicative stress and promotes transformation, J Exp Med, 209, 455, 10.1084/jem.20112147 Tibbetts, 2000, Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress, Genes Dev, 14, 2989, 10.1101/gad.851000 Reinhardt, 2007, P53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage, Cancer Cell, 11, 175, 10.1016/j.ccr.2006.11.024 Kyriakis, 2001, Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation, Physiol Rev, 81, 807, 10.1152/physrev.2001.81.2.807 Tanoue, 2001, Identification of a docking groove on ERK and p38 MAP kinases that regulates the specificity of docking interactions, EMBO J, 20, 466, 10.1093/emboj/20.3.466 Smith, 2000, Creation of a stress-activated p90 ribosomal S6 kinase. The carboxyl-terminal tail of the MAPK-activated protein kinases dictates the signal transduction pathway in which they function, J Biol Chem, 275, 31588, 10.1074/jbc.M005892200 Raman, 2007, TAO kinases mediate activation of p38 in response to DNA damage, EMBO J, 26, 2005, 10.1038/sj.emboj.7601668 Manke, 2005, MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase progression in response to UV irradiation, Mol Cell, 17, 37, 10.1016/j.molcel.2004.11.021 Reinhardt, 2010, DNA damage activates a spatially distinct late cytoplasmic cell-cycle checkpoint network controlled by MK2-mediated RNA stabilization, Mol Cell, 40, 34, 10.1016/j.molcel.2010.09.018 Ma, 2004, A biochemically defined system for mammalian nonhomologous DNA end joining, Mol Cell, 16, 701, 10.1016/j.molcel.2004.11.017 Lieber, 2008, Flexibility in the order of action and in the enzymology of the nuclease, polymerases, and ligase of vertebrate non-homologous DNA end joining: relevance to cancer, aging, and the immune system, Cell Res, 18, 125, 10.1038/cr.2007.108 Sung, 2006, Mechanism of homologous recombination: mediators and helicases take on regulatory functions, Nat Rev Mol Cell Biol, 7, 739, 10.1038/nrm2008 D’Andrea, 2003, The Fanconi anaemia/BRCA pathway, Nat Rev Cancer, 3, 23, 10.1038/nrc970 Wang, 2007, Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins, Nat Rev Genet, 8, 735, 10.1038/nrg2159 Duensing, 2002, The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability, Cancer Res, 62, 7075 Havre, 1995, P53 inactivation by HPV16 E6 results in increased mutagenesis in human cells, Cancer Res, 55, 4420 Deng, 2012, Pericentromeric regions are refractory to prompt repair after replication stress-induced breakage in HPV16 E6E7-expressing epithelial cells, PLoS ONE, 7, e48576, 10.1371/journal.pone.0048576 Chen, 2009, Human papilloma virus type16 E6 deregulates CHK1 and sensitizes human fibroblasts to environmental carcinogens independently of its effect on p53, Cell Cycle, 8, 1775, 10.4161/cc.8.11.8724 Giampieri, 2004, Repair of UV-induced thymine dimers is compromised in cells expressing the E6 protein from human papillomaviruses types 5 and 18, Br J Cancer, 90, 2203, 10.1038/sj.bjc.6601829 Wallace, 2012, HPV 5 and 8 E6 abrogate ATR activity resulting in increased persistence of UVB induced DNA damage, PLoS Pathog, 8, e1002807, 10.1371/journal.ppat.1002807 Ford, 1998, Human fibroblasts expressing the human papillomavirus E6 gene are deficient in global genomic nucleotide excision repair and sensitive to ultraviolet irradiation, Cancer Res, 58, 599 Ferguson, 2005, Proficient global nucleotide excision repair in human keratinocytes but not in fibroblasts deficient in p53, Cancer Res, 65, 8723, 10.1158/0008-5472.CAN-05-1457 Srivenugopal, 2002, The DNA repair protein, O(6)-methylguanine-DNA methyltransferase is a proteolytic target for the E6 human papillomavirus oncoprotein, Oncogene, 21, 5940, 10.1038/sj.onc.1205762 McHugh, 2001, Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance, Lancet Oncol, 2, 483, 10.1016/S1470-2045(01)00454-5 Doles, 2010, Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapy, Proc Natl Acad Sci USA, 107, 20786, 10.1073/pnas.1011409107 Savitsky, 1995, A single ataxia telangiectasia gene with a product similar to PI-3 kinase, Science, 268, 1749, 10.1126/science.7792600 Shiloh, 2003, ATM and related protein kinases: safeguarding genome integrity, Nat Rev Cancer, 3, 155, 10.1038/nrc1011 Riballo, 2004, A pathway of double-strand break rejoining dependent upon ATM, Artemis, and proteins locating to gamma-H2AX foci, Mol Cell, 16, 715, 10.1016/j.molcel.2004.10.029 Cremona, 2014, ATM signalling and cancer, Oncogene, 33, 3351, 10.1038/onc.2013.275 Cerami, 2012, The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data, Cancer Discov, 2, 401, 10.1158/2159-8290.CD-12-0095 Gao, 2013, Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal, Sci Signal, 6, pl1, 10.1126/scisignal.2004088 Roossink, 2012, The role of ATM and 53BP1 as predictive markers in cervical cancer, Int J Cancer, 131, 2056, 10.1002/ijc.27488 Powell, 1995, Differential sensitivity of p53(−) and p53(+) cells to caffeine-induced radiosensitization and override of G2 delay, Cancer Res, 55, 1643 Kelland, 1988, Modification of radiation dose-rate sparing effects in a human carcinoma of the cervix cell line by inhibitors of DNA repair, Int J Radiat Biol, 54, 229, 10.1080/09553008814551671 Sarkaria, 1999, Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine, Cancer Res, 59, 4375 Price, 1996, The phosphatidylinositol 3-kinase inhibitor wortmannin sensitizes murine fibroblasts and human tumor cells to radiation and blocks induction of p53 following DNA damage, Cancer Res, 56, 246 Sarkaria, 1998, Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin, Cancer Res, 58, 4375 Hickson, 2004, Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM, Cancer Res, 64, 9152, 10.1158/0008-5472.CAN-04-2727 Golding, 2009, Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion, Mol Cancer Ther, 8, 2894, 10.1158/1535-7163.MCT-09-0519 Batey, 2013, Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer, Mol Cancer Ther, 12, 959, 10.1158/1535-7163.MCT-12-0707 Biddlestone-Thorpe, 2013, ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation, Clin Cancer Res, 19, 3189, 10.1158/1078-0432.CCR-12-3408 Rainey, 2008, Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation, Cancer Res, 68, 7466, 10.1158/0008-5472.CAN-08-0763 de Klein, 2000, Targeted disruption of the cell-cycle checkpoint gene ATR leads to early embryonic lethality in mice, Curr Biol, 10, 479, 10.1016/S0960-9822(00)00447-4 Nishida, 2009, Inhibition of ATR protein kinase activity by schisandrin B in DNA damage response, Nucleic Acids Res, 37, 5678, 10.1093/nar/gkp593 Charrier, 2011, Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents, J Med Chem, 54, 2320, 10.1021/jm101488z Gamper, 2013, ATR kinase activation in G1 phase facilitates the repair of ionizing radiation-induced DNA damage, Nucleic Acids Res, 41, 10334, 10.1093/nar/gkt833 Toledo, 2011, A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations, Nat Struct Mol Biol, 18, 721, 10.1038/nsmb.2076 Maira, 2008, Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity, Mol Cancer Ther, 7, 1851, 10.1158/1535-7163.MCT-08-0017 Arris, 2000, Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles, J Med Chem, 43, 2797, 10.1021/jm990628o Peasland, 2011, Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines, Br J Cancer, 105, 372, 10.1038/bjc.2011.243 Foote, 2013, Discovery of 4-{4-[(3R)-3-methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity, J Med Chem, 56, 2125, 10.1021/jm301859s Reaper, 2011, Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR, Nat Chem Biol, 7, 428, 10.1038/nchembio.573 Fokas, 2012, Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation, Cell Death Dis, 3, 10.1038/cddis.2012.181 Kurimasa, 1999, Requirement for the kinase activity of human DNA-dependent protein kinase catalytic subunit in DNA strand break rejoining, Mol Cell Biol, 19, 3877, 10.1128/MCB.19.5.3877 Jeggo, 1989, Sensitivity of Chinese hamster ovary mutants defective in DNA double strand break repair to topoisomerase II inhibitors, Cancer Res, 49, 7057 Beskow, 2009, Radioresistant cervical cancer shows upregulation of the NHEJ proteins DNA-PKcs, Ku70 and Ku86, Br J Cancer, 101, 816, 10.1038/sj.bjc.6605201 Collis, 2005, The life and death of DNA-PK, Oncogene, 24, 949, 10.1038/sj.onc.1208332 Leahy, 2004, Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries, Bioorg Med Chem Lett, 14, 6083, 10.1016/j.bmcl.2004.09.060 Willmore, 2004, A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia, Blood, 103, 4659, 10.1182/blood-2003-07-2527 Zhao, 2006, Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441, Cancer Res, 66, 5354, 10.1158/0008-5472.CAN-05-4275 Zhou, 2013, DNA-PKcs inhibition sensitizes cancer cells to carbon-ion irradiation via telomere capping disruption, PLoS ONE, 8, e72641, 10.1371/journal.pone.0072641 Shang, 2010, Inactivation of DNA-dependent protein kinase leads to spindle disruption and mitotic catastrophe with attenuated checkpoint protein 2 phosphorylation in response to DNA damage, Cancer Res, 70, 3657, 10.1158/0008-5472.CAN-09-3362 An, 2010, DNA-PKcs plays a dominant role in the regulation of H2AX phosphorylation in response to DNA damage and cell cycle progression, BMC Mol Biol, 11, 18, 10.1186/1471-2199-11-18 Munck, 2012, Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K, Mol Cancer Ther, 11, 1789, 10.1158/1535-7163.MCT-11-0535 Zhang, 2005, BRCA1 interaction with human papillomavirus oncoproteins, J Biol Chem, 280, 33165, 10.1074/jbc.M505124200 Bindra, 2004, Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells, Mol Cell Biol, 24, 8504, 10.1128/MCB.24.19.8504-8518.2004 Vaupel, 2001, Treatment resistance of solid tumors: role of hypoxia and anemia, Med Oncol, 18, 243, 10.1385/MO:18:4:243 Rockwell, 1997, Oxygen delivery: implications for the biology and therapy of solid tumors, Oncol Res, 9, 383 Matsuoka, 2000, Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro, Proc Natl Acad Sci USA, 97, 10389, 10.1073/pnas.190030497 Zhao, 2001, ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1, Mol Cell Biol, 21, 4129, 10.1128/MCB.21.13.4129-4139.2001 Peng, 1997, Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216, Science, 277, 1501, 10.1126/science.277.5331.1501 Sørensen, 2005, The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair, Nat Cell Biol, 7, 195, 10.1038/ncb1212 Zenvirt, 2010, Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents, Oncogene, 29, 6149, 10.1038/onc.2010.343 Beeharry, 2013, Centromere fragmentation is a common mitotic defect of S and G2 checkpoint override, Cell Cycle, 12, 1588, 10.4161/cc.24740 Chen, 2012, Inhibition of Eg5 acts synergistically with checkpoint abrogation in promoting mitotic catastrophe, Mol Cancer Res, 10, 626, 10.1158/1541-7786.MCR-11-0491 Sommers, 1998, Multimodality therapy: radiation and continuous concomitant cis-platinum and PKC inhibition in a cervical carcinoma model, Cancer Invest, 16, 462, 10.3109/07357909809011700 Wagner, 2009, Cisplatin-induced DNA damage activates replication checkpoint signaling components that differentially affect tumor cell survival, Mol Pharmacol, 76, 208, 10.1124/mol.109.055178 Bunch, 1996, Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor, Clin Cancer Res, 2, 791 Zhao, 2002, Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints, Proc Natl Acad Sci USA, 99, 14795, 10.1073/pnas.182557299 Ma, 2011, Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics, Trends Mol Med, 17, 88, 10.1016/j.molmed.2010.10.009 Ma, 2013, A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer, Breast Cancer Res Treat, 137, 483, 10.1007/s10549-012-2378-9 Welch, 2007, UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium, Gynecol Oncol, 106, 305, 10.1016/j.ygyno.2007.02.018 Li, 2012, A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial, Invest New Drugs, 30, 741, 10.1007/s10637-010-9562-8 Rini, 2004, Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinoma, Cancer, 101, 90, 10.1002/cncr.20313 Fuse, 1998, Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein, Cancer Res, 58, 3248 Zabludoff, 2008, AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies, Mol Cancer Ther, 7, 2955, 10.1158/1535-7163.MCT-08-0492 Morgan, 2010, Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair, Cancer Res, 70, 4972, 10.1158/0008-5472.CAN-09-3573 Seto, 2013, Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours, Cancer Chemother Pharmacol, 72, 619, 10.1007/s00280-013-2234-6 Sausville, 2014, Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors, Cancer Chemother Pharmacol, 73, 539, 10.1007/s00280-014-2380-5 King, 2014, Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor, Invest New Drugs, 32, 213, 10.1007/s10637-013-0036-7 Bulavin, 2001, Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase, Nature, 411, 102, 10.1038/35075107 Gurgis, 2014, Mitogen-activated protein kinase-activated protein kinase 2 in neuroinflammation, heat shock protein 27 phosphorylation, and cell cycle: role and targeting, Mol Pharmacol, 85, 345, 10.1124/mol.113.090365 Halazonetis, 2008, An oncogene-induced DNA damage model for cancer development, Science, 319, 1352, 10.1126/science.1140735